ClinicalTrials.gg
CompletedNCT00769171DRAGONUpdated Dec 18, 2014

Dragon Study (the Safety and Efficacy for Treatment of Patients With Complicated Intra Abdominal Infections)

A Phase 3 interventional study of Avelox (Moxifloxacin, BAY12-8039) and Ceftriaxone + Metronidazole in Infection, Intra-abdominal, sponsored by Bayer. Completed at 25 sites in 6 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2014-12-18.

Sponsored by Bayer · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
364
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 22 studies in Intraabdominal Infections with a site in China — 6 open to participants now, 6 under way, 1 of them phase 3. Intraabdominal Infections · China.

Enrollment
7th of 17
364 · median 268
Started
2005
with 1 other
Phase 3
5 of 22
1 open now
Registered
2nd of 22
by date
Lead sponsor
1 of 22
Bayer

Among the 22 studies in Intraabdominal Infections with a site in China, this one is the 7th largest by enrollment of the 17 interventional ones that give a count, is one of 2 that started in 2005, is one of 5 in phase 3, and was the 2nd registered.

Intraabdominal Infections

129 studies on the registry are indexed under Intraabdominal Infections; 15 are open to participants now.

Browse Intraabdominal Infections studies →

Open to participants now

6 of the 22 studies in Intraabdominal Infections with a site in China are open now. Recruiting first, the newest first:

1 more — sign in →

All 6 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 10 Intraabdominal Infections studies recruiting now, 6 (60%) set no upper age limit and 3 (30%) stop at 75 or younger; 2 take children under 18; 2 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 22 studies in Intraabdominal Infections with a site in China, or all of them as a file.
02

Study summary

The purpose of this study is to assess the safety and efficacy of intravenous administration Moxifloxacin (BAY 12-8039) compared to intravenous ceftriaxone and metronidazole for the treatment of patients with complicated intra abdominal infections. In view of the fact that intra abdominal infections are typically polymicrobial and are often treated empirically, the selected antibacterial agent must cover the likely spectrum of bacterial pathogens. Combination antibiotics therapy has been widely used with great success.

03

Conditions studied

  • Infection, Intra-abdominal

Keywords

  • Complicated Intra-Abdominal Infections
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Hospitalized males or females >/= 18 years of age
  • Expected duration of treatment with intravenous antibiotics in hospital is anticipated to be >/= 3 full days but not exceeding 14 days
  • Ability to provide written
  • Confirmed or suspected intra abdominal infection through surgical procedure or Radiological evidence. For suspected intra abdominal infection, The patient must be scheduled for a surgical procedure

Exclusion criteria

Exclusion Criteria:

  • Known to fluoroquinolones, or other quinolones, and/or to beta lactams antibiotic drugs, or metronidazole or any of the . History of tendon disease/disorder related to quinolone treatment
  • Known congenital or documented acquired ; uncorrected hypokalemia; bradycardia; clinically relevant heart failure with reduced ; previous history of symptomatic arrhythmias. Concomitant use of any of the following drugs, reported to increase the QT interval:
  • Known severe end stage liver disease ( C)
  • Systemic antibacterial therapy for more than 24 h within 7 days of enrollment
  • Indwelling peritoneal catheter, Pre existing ascites and presumed spontaneous bacterial peritonitis
  • All pancreatic processes including pancreatic sepsis, peripancreatic sepsis, or an intra abdominal infection secondary to pancreatitis
  • Traumatic perforation of the upper gastrointestinal tract (stomach, duodenum) or perforated peptic ulcer if duration of perforation is \< 24 h or if operated on within 24 h of perforation
  • Traumatic perforation of the small or large bowel if duration of perforation is \< 12 h or if operated on within 12 h of perforation
  • Transmural necrosis of the intestine due to acute embolic, thrombotic, or obstructive occlusions
  • Acute cholecystitis with infection confined to the gallbladder unless there is evidence of an abscess or necrotic tissue or purulent exudate surrounding the gallbladder indicating a transition of bacteria and the inflammatory process into the abdominal cavity
  • Early acute or suppurative, nonperforated appendicitis unless there is evidence of an abscess or peritoneal fluid containing leukocytes and micro organisms suggestive of regional contamination
  • Infections originating from the female genital tract. Perinephric infections
  • Severe, life threatening disease with a of \< 48 h or APS and APACHE scores of > 35, Known rapidly fatal underlying disease (death expected within 6 months)
  • Neutropenia ( \< 1,000/microliter) caused by therapy or
  • Patients known to have AIDS or seropositives who are receiving HAART
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
364 participants (actual)

Study arms

  • Active comparator
    Arm 2

    Drug: Ceftriaxone + Metronidazole

  • Experimental
    Arm 1

    Drug: Avelox (Moxifloxacin, BAY12-8039)

Interventions

06

What researchers measure

Primary outcomes

  1. Clinical Response

    Time frame: After 10-14 days of treatment

Secondary outcomes

  1. Clinical and bacteriological response

    Time frame: During 3-5days of treatment

  2. Bacteriological and radiological response

    Time frame: After 10-14 days of treatment

  3. Clinical response at the TOC visit in patients with bacteriological proven intra abdominal infection

    Time frame: After 10-14 days of treatment

  4. Mortality attributable to intra abdominal infection

    Time frame: 13-28 days

07

Study locations

25 sites
  • Nanjing, Jiangsu, China
  • Chengdu, Sichuan 610041, China
  • Hangzhou, Zhejiang 310003, China
  • Beijing, 100044, China
  • Beijing, 100050, China
  • Beijing, 100730, China
  • Beijing, China
  • Shanghai, 200032, China
  • Shanghai, 200127, China
  • Shanghai, 200233, China
  • Shanghai, China
  • Tianjin, 300000, China
  • Shatin, New Territories, Hong Kong
  • Hong Kong, Hong Kong
  • Bandung, West Java 40161, Indonesia
  • Uijeongbu, Kyonggi-do 480-130, Korea, Republic of
  • Incheon, 405-760, Korea, Republic of
  • Seoul, 137-701, Korea, Republic of
  • Seoul, 150-713, Korea, Republic of
  • Seoul, 420-717, Korea, Republic of
  • Kuching, Sarawak 93400, Malaysia
  • Terengganu, 20400, Malaysia
  • Kaoshiung, 813, Taiwan
  • Tainan, 70428, Taiwan
  • Taipei, Taiwan
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2005, a primary completion of Dec 2006 and a completion of Jan 2007. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 7, 2008
First posted
Oct 8, 2008
Start
Oct 2005
Primary completionActual
Dec 2006
CompletionActual
Jan 2007
Last update
Dec 18, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 18, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00769171
Lead sponsor
Bayer
First posted
Oct 8, 2008
Start date
Oct 2005
Primary completion
Dec 2006
Completion
Jan 2007
Last update
Dec 18, 2014

Study contacts

Bayer Study Director
study director · Bayer

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Moxifloxacin

Start the discussion